NEW YORK (GenomeWeb) – Biocept's stock faces a potential delisting from the Nasdaq due to a failure to comply with the minimum bid price requirement, the company said in a filing made yesterday with the US Securities and Exchange Commission.

Biocept received a notice from Nasdaq stating that it had failed to maintain a required minimum closing bid price of at least $1 per share.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Associated Press reports that the US government wasted $341,000 on travel by former Health and Human Services Secretary Tom Price.

Women who post YouTube science videos get more critical comments and more comments about their appearance than male video hosts, the New York Times reports.

The Wall Street Journal writes that participating in genetic research brings up the specter of past research ethics lapses for some African Americans.

In PLOS this week: sequences influencing yeast prion aggregation or degradation, dengue virus genetic variants affect transmission dynamics, and more.